179 related articles for article (PubMed ID: 26043355)
1. Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand.
Wayua C; Roy J; Putt KS; Low PS
Mol Pharm; 2015 Jul; 12(7):2477-83. PubMed ID: 26043355
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.
Wayua C; Low PS
J Nucl Med; 2015 Jan; 56(1):113-9. PubMed ID: 25500824
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer.
Wayua C; Low PS
Mol Pharm; 2014 Feb; 11(2):468-76. PubMed ID: 24325469
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
6. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
7. Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.
Brillouet S; Dorbes S; Courbon F; Picard C; Delord JP; Benoist E; Poirot M; Mestre-Voegtlé B; Silvente-Poirot S
Bioorg Med Chem; 2010 Jul; 18(14):5400-12. PubMed ID: 20542702
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors.
Sanchez C; Escrieut C; Clerc P; Gigoux V; Waser B; Reubi JC; Fourmy D
Mol Cell Endocrinol; 2012 Feb; 349(2):170-9. PubMed ID: 22040601
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a UPLC-MS/MS method for the novel folate-targeted small molecule drug conjugate EC1456 and its metabolites in tumor homogenates from mice.
Rao SI; Pugh M; Nelson M; Reddy JA; Klein PJ; Leamon CP
J Pharm Biomed Anal; 2016 Apr; 122():148-56. PubMed ID: 26855286
[TBL] [Abstract][Full Text] [Related]
10. Multifactorial diagnostic NIR imaging of CCK2R expressing tumors.
Kossatz S; Béhé M; Mansi R; Saur D; Czerney P; Kaiser WA; Hilger I
Biomaterials; 2013 Jul; 34(21):5172-80. PubMed ID: 23591397
[TBL] [Abstract][Full Text] [Related]
11. Development of a Ligand-Targeted Therapeutic Agent for Neurokinin-1 Receptor Expressing Cancers.
Kanduluru AK; Low PS
Mol Pharm; 2017 Nov; 14(11):3859-3865. PubMed ID: 28969417
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue.
Roy J; Putt KS; Coppola D; Leon ME; Khalil FK; Centeno BA; Clark N; Stark VE; Morse DL; Low PS
Oncotarget; 2016 Mar; 7(12):14605-15. PubMed ID: 26910279
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of activation of a G protein-coupled receptor, the human cholecystokinin-2 receptor.
Marco E; Foucaud M; Langer I; Escrieut C; Tikhonova IG; Fourmy D
J Biol Chem; 2007 Sep; 282(39):28779-28790. PubMed ID: 17599907
[TBL] [Abstract][Full Text] [Related]
14. rG17PE38, a novel immunotoxin target to gastric cancer with overexpressed CCK-2R.
Song J; Ren H; Li Y; Xu J; Kong H; Tong W; Zhou Y; Gao S; Liu Y; Hui Q; Peng Q; Lu S; Liu Z
J Drug Target; 2013 May; 21(4):375-82. PubMed ID: 23311704
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
16. Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis.
Quattrone A; Dewaele B; Wozniak A; Bauters M; Vanspauwen V; Floris G; Schöffski P; Chibon F; Coindre JM; Sciot R; Debiec-Rychter M
J Pathol; 2012 Dec; 228(4):565-74. PubMed ID: 22786615
[TBL] [Abstract][Full Text] [Related]
17. Valine-286 residue in the third intracellular loop of the cholecystokinin 2 receptor exerts a pivotal role in cholecystokinin 2 receptor mediated intracellular signal transduction in human colon cancer cells.
Yu HG; Schäfer H; Mergler S; Müerköster S; Cramer T; Höcker M; Herzig KH; Schmidt WE; Schmitz F
Cell Signal; 2005 Dec; 17(12):1505-15. PubMed ID: 15951156
[TBL] [Abstract][Full Text] [Related]
18. Discovery of the cyclotide caripe 11 as a ligand of the cholecystokinin-2 receptor.
Taghizadeh MS; Retzl B; Muratspahić E; Trenk C; Casanova E; Moghadam A; Afsharifar A; Niazi A; Gruber CW
Sci Rep; 2022 Jun; 12(1):9215. PubMed ID: 35654807
[TBL] [Abstract][Full Text] [Related]
19. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase.
Yu HG; Tong SL; Ding YM; Ding J; Fang XM; Zhang XF; Liu ZJ; Zhou YH; Liu QS; Luo HS; Yu JP
Int J Cancer; 2006 Dec; 119(12):2724-32. PubMed ID: 16998832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
